Trial results

$ZURA — Tibulizumab

Zura Bio Ltd (ZURA) Tibulizumab: trial results in Moderate to severe hidradenitis suppurativa, 2026.

Research by Catalyst Intel

The catalyst

"Topline results are expected to be available in the fourth quarter of 2026."

— Zura Bio, Inc., 10-Q filed 2026-10-27 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ZURA-TIBULIZUMAB-2026

Company

Zura Bio Ltd

Kind

Trial results

Indication

Moderate to severe hidradenitis suppurativa

Window

2026-10-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.